Meta-analysis Of MEBT/MEBO In The Treatment Of Chronic Refractory Wounds

Objective:1.Based on the meta-analysis,the clinical efficacy of skin regeneration medical technology(MEBT/MEBO)in chronic refractory wounds was discussed,and the evidence-based basis for its clinical application was provided.2.Through the clinical observation of MEBT/MEBO in the treatment of chronic refractory wounds,the clinical efficacy of MEBT/MEBO in wound repair and its impact on the quality of life of patients were discussed.Methods: 1.Search the CNKI,VIP,Wanfang,NCBI,Pub Med,Cochrane Library database for the literature with MEBT/MEBO therapy as the intervention measure,chronic refractory wound as the diagnosis,and RCT as the research method,from January 2012 to January 2022.The primary outcome indicators included the number of completely cured patients,the area of ulcer before and after treatment,and the time of complete wound healing.The secondary outcome indicators included the frequency of administration,treatment period,and the average age of patients in each study group.RCT quality evaluation is conducted by a professional and a non-professional personnel who have received scientific research training independently complete the research scheme and data scoring of the literature without mutual interference.If there is any dispute about the screening and evaluation process,the third person will conduct a second evaluation and finally obtain the initial data.After extracting data from the documents meeting the requirements of the inclusion criteria according to the observation outcome indicators,Meta analysis was performed on the finally included documents through Review Manager5.3 and Stata17 software.2.The 60 patients were numbered according to the order of enrollment,and were divided into treatment group(MEBO group)and control group(Befuxin group)with 30 patients each according to the method of random number table.Observe the scores of activities of daily living,quality of life and mood of the two groups before and after treatment for 28 days,and then evaluate the curative effect difference between the two drugs.Results: 1.Meta analysis results: The meta-analysis finally included 23 articles,and the results after combining the effects were as follows:(1)The total effective rate,the wound healing time,the time of granulation tissue appearance,the wound healing area,the wound healing rate,the content of VEGF(Vascular Endothelial Growth Factor)and the content of EGF(Epidermal Growth Factor)in the treatment group(MEBO group)for treating chronic refractory wounds VAS score was better than that of the control group(P<0.01);(2)The recurrence rate in the control group was higher than that in the treatment group(OR=0.36,95% CI [0.16,0.82],Z=2.43,P=0.02);(3)The wound infection rate in the treatment group was lower than that in the control group(OR=0.29,95% CI [0.15,0.57],Z=3.61,P=0.0003).2.Clinical observations:After 28 days of treatment,the two groups of patients were both effective in promoting wound healing,of which the total effective rate of the treatment group was 92.9%,and the total effective rate of the control group was 82.8%.There was no statistically significant difference in the total effective rate between the two groups(P>0.05).There were statistically significant differences in activities of daily living(BI score),quality of life(QOL score)and anxiety and depression subscale(HADS score)between the two groups compared with those before treatment(P<0.01);In terms of BI,QOL and HADS scores,the difference between the two groups was statistically significant(P<0.05),indicating that MEBO and Befoxine can both improve BI,QOL scores and reduce HADS scores,and MEBO is significantly higher than Befoxine.Conclusions: 1.The clinical efficacy of MEBO group in treating chronic refractory wounds is better than that of other drugs(control group,iodophor,vaseline,Kangfuxin liquid,Befuxin,soft polysilicone dressing,compound phellodendron solution coating,sulfadiazine throat silver zinc cream),and the recurrence rate and infection rate are low,but it needs to be verified by higher level of evidence-based medical evidence.2.MEBT/MEBO can promote epithelial tissue crawling,reduce wound area,reduce pain,improve wound healing speed,accelerate wound healing,relieve patients’ anxiety and depression,improve patients’ confidence and self-concept ability,and improve patients’ quality of life.